Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
